Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Top Reads

J Immunol June 15, 2020, 204 (12) 3061-3062; DOI: https://doi.org/10.4049/jimmunol.2090008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Anti-Inflammatory Effects of Δ9-THC

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

In this Top Read, Joffre et al. (p. 3339) demonstrate that Δ9-tetrahydrocannabinol (Δ9-THC) has strong and sustained anti-inflammatory properties in mice with acute inflammation. Δ9-THC treatment reduced indices of organ injury and improved the clinical status of endotoxemic mice. Compared with healthy controls, endotoxemic mice receiving Δ9-THC showed an early increase in circulating IL-10 and concomitant decreases in circulating IL-6 and CCL2. The anti-inflammatory effects of Δ9-THC were reversed by administration of a cannabinoid receptor type 1 inverse-agonist. Similar to normal mice, Δ9-THC was anti-inflammatory in splenectomized mice. However, clondronate depletion of monocytes did not increase IL-10 in response to Δ9-THC, suggesting that blood monocytic myeloid-derived suppressive cells were responsible for the Δ9-THC–induced IL-10 upregulation. Blockade of IL-10 receptor signaling did not impact Δ9-THC–induced changes in IL-10, IL-6, or CCL2, implying that the reduction of IL-6 and CCL2 are IL-10 independent. Δ9-THC treatment also reduced activation of innate and adaptive leukocytes in the spleen, most notably, neutrophils, B cells, and CD4+ T cells. As cannabinoids are becoming more widely used, these data suggest the endocannabinoid system may represent a novel therapeutic target for inflammatory disorders and raises the potential of using cannabinoids to promote inflammatory resolution and to reduce organ injury in sepsis and injury.

Regulation of MDSCs by MLL1

Figure2
  • Download figure
  • Open in new tab
  • Download powerpoint

The H3K4 methyltransferase mixed-lineage leukemia 1(MLL1) is required for the regulation of hematopoietic stem cell homeostasis. Whereas disruption of the MLL1-complex is associated with acute leukemia, its exact role in myeloid cells remains unknown. In this Top Read, Zhang et al. (p. 3400) carried out a microarray analysis to identify differentially expressed genes during expansion and activation of myeloid-derived suppressor cells (MDSCs). The core components of the MLL1-complex, Wdr5, Ash21, and Mll1, were concurrently downregulated in activated MDSCs in vitro and in vivo. Overexpression of Wdr5, Ash21, and Mll1 reversed the accumulation and suppressive abilities of polymorphonuclear MDSCs (PMN-MDSC) by promoting them to differentiate into mature neutrophil-like cells. Activation of MDSCs with GM-CSF and IL-6 induced Stat3 and Cebpβ, as well as the expression of miR-21a, miR-21b, and miR-181b, which targeted the 3ʹ untranslated regions of Wdr5, Ash21, and Mll1, respectively. Knockdown of these miRNAs also suppressed expansion and function of PMN-MDSCs induced by GM-CSF and IL-6. Thus, this study identifies a suppressive role for the MLL1-complex in PMN-MDSC expansion, activation, and differentiation that may be targeted therapeutically in patients with cancer or other inflammatory diseases.

IL-1R Tolerance and Cachexia in Toxoplasma gondii infection

Figure3
  • Download figure
  • Open in new tab
  • Download powerpoint

In this Top Read, Melchor et al. (p. 3329) further elucidate the role of IL-1 during Toxoplasma gondii infection. Compared with wild-type (WT) mice, those that were IL-1R–deficient (IL-1R−/−) and infected with T. gondii had increased cell death in the liver and adipose tissue during acute infection. However, IL-1R−/− mice had significantly improved long-term survival with no reduction in parasite burden, implicating a role for IL-1 in disease tolerance rather than resistance. The ability of IL-1R−/− mice to survive chronic infection was associated with their ability to recover from cachexia, an immune-metabolic disease of muscle wasting associated with chronic T. gondii infection. Furthermore, studies using mice deficient in either IL-1α or IL-1β showed that, relative to uninfected controls, both knockout strains where partially protected from weight loss by 12 w postinfection, but failed to fully regain body mass. These data suggest that both IL-1α and IL-1β contribute to chronic cachexia during T. gondii infection. Thus, this study demonstrates that IL-1R signaling triggered by IL-1α and IL-1β plays an important role in the innate inflammatory response during T. gondii infection and indicates a critical function for IL-1R as a regulator of host homeostasis.

Bmi1 Maintains B-1 Cell Self-Renewal Ability

Figure4
  • Download figure
  • Open in new tab
  • Download powerpoint

One of the most striking features of murine fetal-derived innate-like CD5+ B-1 (B-1a) cells, is their unique origin and self-replenishing ability. However, the mechanism by which these IgM-secreting cells self-renew is poorly understood. In this Top Read, Kobayashi et al. (p. 3262) show that compared with other lymphoid cell subsets, Bmi1 is highly expressed in B-1a cells. Whereas deletion of Bmi1 did not alter the number of mature conventional B cells, the number of peritoneal B-1a cells was significantly reduced. Bmi1-deficient peritoneal B-1a cells lost their self-renewal ability upon transplantation into wild type mice. However, self-renewal ability of Bmi1-deficient cells was restored either by overexpression of Bmi1 or deletion of Ink4-Arf, a well-known target of Bmi1. Furthermore, transplantation of fetal liver cells with a B cell–specific deletion of Bmi1 failed to repopulate peritoneal B-1a cells, suggesting that Bmi1 may be involved in the development of B-1 progenitors to mature B-1a cells. Deletion of Bmi1, however, did not alter fat-associated lymphoid clusters, the reported niche for B-1a cells. Microarray analysis suggested that lysine demethylase 5B (Kdm5b) as another possible target of Bmi1, which was elevated in Bmi1-deficient B-1a cells in a stress setting, suggesting that Kdm5b may also regulate self-renewal. Thus, this study demonstrates that Bmi1 plays a vital role in self-renewal and maintenance of fetal-derived B-1a cells, which is an important step in developing pluripotent stem cell–derived B-1 cells for immune cell therapy.

UHRF1 Controls Thymocyte Fate Decisions via EGR1

Figure5
  • Download figure
  • Open in new tab
  • Download powerpoint

In this Top Read, Zhang et al. (p. 3248) showed that ubiquitin-like containing PHD ring finger 1 (UHRF1) is an epigenetic modifier that controls thymocyte development. A significant reduction in thymocyte cellularity and thymus size was observed in mice with a conditional knock out, in which thymocytes specifically lacked UHRF1(Uhrf1−/−). Single cell RNA sequence analysis revealed an accumulation of double negative (DN) and immature single positive (ISP) thymocytes in Uhrf1−/− mice, suggesting a role in the developmental transition from DN to double positive (DP). The role of UHRF1 was specific to αβ T cell lineages, which was confirmed using mixed bone marrow chimeric mice wherein the Urf1−/− cells were enriched for IL-17+ RORγt+ γδ T cells. The loss of UHRF1 resulted in uncontrolled expression of early growth response 1 (EGR1), which enhanced γδ T development and impaired αβ T cell development. Compared with wild type cells, Uhrf1−/− thymocytes had a significantly different pattern of H3K9me3 and H3K4me3 near the Egr1 promoter. These data indicate that UHRF1 represses EGR1 through epigenetic modifications during thymic development.

Adjuvant Properties of Endogenous Phospholipase A2

Figure6
  • Download figure
  • Open in new tab
  • Download powerpoint

In this Top Read, Ogden et al. (p. 3097) demonstrate that a recombinant version of a secreted endogenous phospholipase A2 group X (sPLA2-X) protein can act as an adjuvant during peripheral sensitization to inhaled Ags. Following airway challenge with OVA, mice sensitized with i.p. injections of sPLA2-X plus OVA showed an increase in airway hyperresponsiveness and increases in the recruitment of type 2 immune cells to the airway, cytokine production by lung leukocytes, and serum levels of IgE and IgG. Studies using a mutant version of sPLA2-X, which lacked enzymatic activity but maintained secondary protein structure, showed that the adjuvant properties of sPLA2-X in the lung are dependent on its enzymatic activity. However, the enzymatic activity of sPLA2-X was not required for increased recruitment of innate lymphoid cells into the peritoneum, suggesting that different adjuvant pathways are required for innate and adaptive immune responses to sPLA2-X. These results, combined with those from a previous study with bee venom PLA2, indicate that endogenous PLA2 may act as an adjuvant to increase sensitivity to exogenous Ags in the lung.

miR-21 Controls Glycolysis of Pathogenic TH17 Cells

Figure7
  • Download figure
  • Open in new tab
  • Download powerpoint

Activation of lymphocytes results in enhanced cellular metabolism via glycolytic pathways. In this Top Read, Qiu et al. (p. 3160) sought to characterize the networks regulating glycolysis in pathogenic TH17 cells. Compared with homeostatic TH17 cells from the ileum, analysis of pathogenic TH17 cells from the CNS of mice with experimental autoimmune encephalomyelitis (EAE) showed upregulation of glycolytic pathway genes. TH17 cells derived in vitro showed enhanced chromatin accessibility at glycolytic genes with NF-κB binding sites and also showed that miR-21 targets the E3 ubiquitin ligase Peli1–c-Rel pathway to promote glucose metabolism in TH17 cells. Consistent with these observations, pharmaceutical inhibition of this pathway reduced expression of key glycolytic pathway gene expression in activated, pathogenic TH17 cells and prevented the development of EAE. Thus, this study identifies the miR-21–Peli1–c-Rel axis as a key metabolic regulator of pathogenic TH17 cells and identifies a possible therapeutic target for the treatment of TH17-mediated autoimmune disorders.

  • Copyright © 2020 by The American Association of Immunologists, Inc.
Next
Back to top

In this issue

The Journal of Immunology: 204 (12)
The Journal of Immunology
Vol. 204, Issue 12
15 Jun 2020
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Advertising (PDF)
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Top Reads
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Top Reads
The Journal of Immunology June 15, 2020, 204 (12) 3061-3062; DOI: 10.4049/jimmunol.2090008

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Top Reads
The Journal of Immunology June 15, 2020, 204 (12) 3061-3062; DOI: 10.4049/jimmunol.2090008
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Anti-Inflammatory Effects of Δ9-THC
    • Regulation of MDSCs by MLL1
    • IL-1R Tolerance and Cachexia in Toxoplasma gondii infection
    • Bmi1 Maintains B-1 Cell Self-Renewal Ability
    • UHRF1 Controls Thymocyte Fate Decisions via EGR1
    • Adjuvant Properties of Endogenous Phospholipase A2
    • miR-21 Controls Glycolysis of Pathogenic TH17 Cells
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Top Reads
  • Top Reads
  • Top Reads
Show more TOP READS

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606